Drug data last refreshed 16h ago · AI intelligence enriched 4w ago
TAGAMET (cimetidine) is an oral small-molecule tablet approved in 1977 as an H2-receptor antagonist for acid-related gastrointestinal disorders. It reduces stomach acid production and is used to treat peptic ulcers, gastroesophageal reflux disease (GERD), and related conditions. The drug represented a major therapeutic advance in the 1970s-80s before proton pump inhibitors (PPIs) became the standard of care.
This legacy product faces steep competitive pressure (30/100) and approaching loss of exclusivity, signaling a contracting team focused on managed decline and cost optimization rather than growth initiatives.
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
TAGAMET roles are primarily operational and compliance-focused rather than growth-oriented, reflecting a legacy product in managed decline. Career advancement on this product typically leads to other GSK franchises or external roles, as the brand offers limited strategic visibility or revenue upside.
Worked on TAGAMET at GSK? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.